MIAMI, Fla., May 1, 2014 /PRNewswire-iReach/ -- MIAMI--May 1, 2014--Medvax Technologies, Inc. ("Medvax" or the "Company) announced today the appointment of Dr. Marc E. Lippman, M.D. as Chair of the Scientific Board.
Dr. Lippman is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard M. Miller School of Medicine, and Deputy Director of the Sylvester Comprehensive Cancer Center. Previously, he served as the John G. Searle Professor and Chairman of the Department of Internal Medicine at the University of Michigan School of Medicine. Before that, Dr. Lippman was the Director of the Lombardi Cancer Research Center, Professor and Chairman of the Department of Oncology, and Professor of Medicine at Georgetown University Medical School. He also served as Chief of the Division of Hematology-Oncology at Georgetown University Medical School and Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute. Dr. Lippman has authored more than 400 peer-reviewed publications and one of the standard texts on breast cancer. Dr. Lippman has served as a Director of Seattle Genetics since June 2000. He received a B.A., magna cum laude from Cornell and his M.D. from Yale where he was elected to Alpha Omega Alpha.
About Medvax Technologies, Inc.
Medvax Technologies, Inc. (www.medvax.net) is a clinical-stage biopharmaceutical company focused on developing cancer vaccine immunotherapies. The Company is developing two lead products of cancer vaccines, focused on Antigen Presenting Cells (APC's) of the immune system. MX-225 is an autologous P53 dendritic cell vaccine that recently completed Phase II (a) clinical trials in Small Cell Lung Cancer and an ongoing Phase II trial in Breast cancer at Moffitt Cancer Center. MX-402 is a non-autologous "off-the-shelf" HER-2 Peptide vaccine currently completing a 2nd Phase 1 clinical trial in solid tumors at the James Cancer Center, Ohio State University.
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect Medvax's current expectations about its future results, performance, prospects and opportunities. Where possible, Medvax has tried to identify these forward-looking statements by using words such as "anticipates", "believes", "intends", or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Medvax cannot assure you that it will be able to successfully develop or commercialize these products or its business strategy will be successful. Medvax assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, changes in circumstances or for any other reason.
Medvax Technologies, Inc.
VP of Business Administration & Public Relations
(305) 371-2301 (Phone)
(305) 371-2304 (Fax)
email@example.comSource: Medvax Technologies, Inc.
Media Contact: Candace Cobos, Medvax Technologies, Inc., (305) 371-2301, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Medvax Technologies, Inc.